Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Chiome Bioscience, Chugai Pharma Terminate Partnership December 17, 2017 Waiting Lists are Already Forming for Novartis AG and Kite Pharma's Not-Yet Approved CAR-T Drugs July 6, 2017 <b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec September 17, 2017
Waiting Lists are Already Forming for Novartis AG and Kite Pharma's Not-Yet Approved CAR-T Drugs July 6, 2017
<b>Kaleido Biosciences</b> Emerges From Stealth Mode With $65 Million and Will be Helmed by Fomer Cubist Exec September 17, 2017